Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 4 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Carcinoma, Transitional Cell 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombocytosis 1 Testicular Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Solid Cancer 1 Recurrence 1 Rectal Neoplasms 1 Radiation Pneumonitis 1 Primary Myelofibrosis 1

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡